MiWendo Solutions, Kamleon and Corify Care share their experiences at the annual workshop of the interuniversity PhD Program in Bioinformatics CREB UPC participated in the digital Workshop of the Interuniversity PhD Program in Bioinformatics, a session where the students defended their thesis in three minutes, but also had an opportunity to learn from other voices in the industry. Open by Toni Manzano from Aizon, the conference included the roundtable “Entrepreneurship in the Healthtech Industry”, where different start-ups’ promoters shared their experience. Marta Guardiola, Co-Founder and CTO of MiWendo Solutions, Jordi Ferré, Co-Founder and CEO of Kamleon and Andreu Climent, Associate Founder and CEO of Corify Care talked from their experience and gave some unique tips to the futureentrepreneurs in the healthtech ecosystem. “I would recommend current generations to identify and talk to the companies that are trying to innovate in their field. It would be stimulating to learn from these possible partners, as well as paying attention to the Key Opinion Leaders in the Science area”, explained Andreu Climent from Corify Care, start-up company, which is going to introduce a novel medical device to non-invasively map cardiac arrhythmias in real time. The speakers also discussed the challenges faced during the incubation process and the time needed to transform an idea into a product. “In our case, it took us around four to five years to bring our technology to the market, but it depends on every project and product”, commented Jordi Ferré, from Kamleon, science-based early-stage company developing user-centered technologies to empower healthier lives by democratizing the monitoring of wellbeing.  Thinking outside the lab and bringing technology to the market sometimes seems to be the hardest part, nevertherless it is not the only key to success. “A well-balanced team, with all the expertise needed to develop the project, is essential”, […]
Exheus Exheus is a young and highly disruptive med tech company. We analyze gene expression in blood samples by applying next-generation sequencing technology (NGS) andartificial intelligence algorithms to offer our customers real and actionable information on their health status at any given moment and condition.The test can be performed many times a year and the evolution of the selected parameters allows to track the progress. What We Are Looking for We are seeking a talented PhD in bioinformatics, computer science, mathematical modeling, big data analysis or related area swith knowledge and experience in management and analysis of transcriptomic data and next-generation sequencing data. Professional experience •Experience in managing, processing, performing quality control and analysis of large amounts of Next Generation Sequencing data. •Good level of statistical programming(R, Python, SQLand others). •Demonstrated knowledge of statistical principles, including experimental design and machine learning. •Strong skills in data visualizationtools. •Demonstrated success in technical proficiency, scientific creativity, collaboration with others and independent thought. Languages •Fluent in English. Main tasks •The job will involve several tasks such asanalysis of gene expression of RNA-seq data and developing custom software for the data visualization. •Develop and optimize scripts, analysis pipelines and reports for routine NGS and genomic data processing. •Optimize our proprietarymachine learning algorithms to improve ourproducts. •Extend the analytics and visualization of capabilities of in-house developed dashboards. •Interact with the research team. Skills •Good organizational skills. •Team player. •Drive and determination. •Desire to learn. •Enjoy solving problems;engaged and motivated. •Ability to communicate effective both verbally and in writing. The Offer –Working Conditions •Contract duration: 1 year with possibility of extension to 3more years by a successful application to a Torres Quevedo Grantor othercalls. •Estimated annual gross salary: Salary is commensurate with qualifications and consistent with our pay scales. •Target start date: January 2021. Application Procedure All […]
We are looking for a highly motivated, dynamic and creative PhD student to work in the field of plasma medicine to investigate its effects on biomaterials (essentially polymers, namely hydrogels), for cancer and regenerative medicine applications. The ultimate goal is to gain fundamental understanding on the effects of plasma-treated hydrogels on cancer and healthy cells and tissues to implement new strategies for local and minimally invasive cancer therapy. If selected, the candidate will work in a multidisciplinary research group focused on the search for potential anti-cancer treatments in human osteosarcoma, specifically the use of Cold Plasmas at atmospheric pressure on biomaterials, cell lines and primary cells, within an ERC project. This position is part of the Starting Grant “APACHE” of the European Research Council. The selected candidate will occupy a full-time place in the plasma medicine research group, led by Dr. Cristina Canal, in the Biomaterials, Biomechanics and Tissue Engineering Research Group ofthe Technical University of Catalonia at EEBE (Campus Diagonal Besòs), Barcelona (https://ercapache.upc.edu/en ). You will be working in a vibrant interdisciplinary research environment involving plasma physics, biomaterials science and cell biology. You will have access to state-of-the-art experimental facilities, will have travel allowance. You will be expected to deliver top quality research. REQUIREMENTSThe successful candidate will hold a master degree in biomedical engineering, tissue engineering, chemistry, biology and other related areas. Previous exposure to plasma medicine, biomaterials or tissue engineering is highly desirable. However, willingness and motivation to expand your expertise by reaching out to other disciplines is required. You are expected to be proficient in English, and have skills in teamwork and communication skills. The evaluation of the candidate will be based on previous studies, credentials, research experience, exposure to relevant disciplines and proficiency in English. Beside skype interviews, it is possible to arrange on site visits […]
The MITEF Spain Jury has reached this decision considering their business model, technology, market potential and evolution, and the team itself. They have developed a technology that is capable of sequencing RNA, from a small blood sample, and associating the expression of genes in more than 320 metabolic pathways that act as biomarkers of the parameters of the individual’s body, analyzing all those variations that are out of the ordinary to improve and prevent health problems. This project was born as a result of the doctoral thesis, defended at the UPC, of ​​the researcher Emma Roca, a biochemist and elite ultra-distance runner. Roca wanted to analyze the impact of high intensity sport on the runners of an ultra-Trail together with Dr. Jose Manuel Soria, principal investigator of the Genomics of Complex Diseases Research Group of the IIB Sant Pau – Fundació Institut de Recerca Hospital de Sant Pau – Centre CERCA and Dr. Alexandre Perera, physicist, expert in Artificial Intelligence and director of the CREB|UPC, in charge of developing the algorithms that allow the expression of metabolic pathways to be automatically evaluated. Finally, within the framework of the Collider program, in the 2019 edition, Dr. Teresa Tarragó, CEO of the project, and Pol Cervera, director of operations, joined in to give the business perspective and face the market. Congratulations to the whole Exheus Team! Awesome work!
The improvement of the quality and life expectation of people with rare diseases was the goal of the La Marató 2019. Along the year, different research projects applied to these funds and finally three of the projects receiving funds will be participated by CREB UPC research groups. These are the following:  ”Use of artificial intelligence and biology systems for the diagnosis and personalized risk assessment for inherited kidney disease, focusing on Alport syndrome”, in which Montserrat Vallverdú Ferrer along with more B2SLab researchers are involved. This project counts with a 399.312,50 € funding. “ArmTracker: A portable system for assessing motor function of the upper extremities during daily life for patients with Duchenne muscular dystrophy and spinal muscular atrophy”,  in whichJosep Maria Font Llagunes along with several BIOMEC & BIOART researchers are involved. This project counts with a 364.053,75 € funding. “Development of personalized treatments in rare genetic diseases causing pediatric parkinsonism”, led by Angels Garcia Cazorla and supported by B2SLab & BIOART researchers, among other. This project counts with a 361.752,49 € funding. Congratulations to our researchers and partners and of course, congratulations to the rest of the projects.